GAITHERSBURG, Md., Nov. 1, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology
company dedicated to developing and commercializing next-generation
vaccines for serious infectious diseases, today announced it will
report its third quarter 2022 financial results and operational
highlights on Tuesday, November 8,
2022, following the close of U.S. financial markets. Details
of the event and replay are as follows:
|
Conference call
details:
|
|
|
Date:
|
November 8,
2022
|
|
Time:
|
4:30 p.m. U.S. Eastern
Daylight Time (EDT)
|
|
Dial-in
number:
|
833) 974-2381
(Domestic) or (412) 317-5774 (International)
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request
to join the Novavax, Inc. call.
- To ensure a timely connection, it is
recommended that participants join at least 10 minutes prior to the
scheduled webcast.
|
|
Replay
details:
|
|
|
Date:
|
Available starting at
7:30 p.m. EDT, November 8, 2022 until 11:59 p.m. U.S. EDT, November
15, 2022
|
|
Dial-in
number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
|
Passcode:
|
3408655
|
|
Webcast:
|
ir.novavax.com/events,
until February 8, 2023
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that
promotes improved health globally through the discovery,
development, and commercialization of innovative vaccines to
prevent serious infectious diseases. The company's proprietary
recombinant technology platform harnesses the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles designed to address urgent global health needs. The
Novavax COVID-19 vaccine has received authorization from multiple
regulatory authorities globally, including the U.S. Food and Drug
Administration, the European Commission, and the WHO. The vaccine
is currently under review by multiple regulatory agencies
worldwide, including for additional populations and indications
such as adolescents and as a booster. In addition to its COVID-19
vaccine, Novavax is also currently evaluating its CIC vaccine
candidate in a Phase 1/2 clinical trial, its quadrivalent influenza
investigational vaccine candidate, and an Omicron strain-based
vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based /
original strain-based vaccine. These vaccine candidates incorporate
Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the
immune response and stimulate high levels of neutralizing
antibodies.
For more information, visit www.novavax.com and connect with us
on LinkedIn.
Contacts:
Investors
Erika Schultz |
240-268-2022
ir@novavax.com
Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2022-financial-results-and-operational-highlights-on-november-8-2022-301665315.html
SOURCE Novavax, Inc.